TABLE 4.
Association between timing of primaquine use relative to chloroquine administration and prospective risk of Plasmodium vivax recurrence over 180 days in the per-protocol study population
| Cox model | Concomitant CQ-PQ (arm 2) vs sequential CQ-PQ (arm 1) |
||
|---|---|---|---|
| Hazard ratio | 95% confidence interval | P value | |
| Unadjusted | 1.421 | 0.807–2.502 | 0.224 |
| Adjusted for age | 1.493 | 0.847–2.634 | 0.166 |
| Adjusted for gender | 1.395 | 0.792–2.457 | 0.250 |
| Adjusted for CYP2D6 activity | 1.254 | 0.703–2.237 | 0.443 |
| Adjusted for age and gender | 1.379 | 0.779–2.439 | 0.270 |
| Adjusted for age, gender, and CYP2D6 activity | 1.248 | 0.698–2.231 | 0.322 |